MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,920.00
-60.00 (-0.86%)
At close: Dec 5, 2025
44.62%
Market Cap 237.18B
Revenue (ttm) 2.47B
Net Income (ttm) -14.57B
Shares Out 34.28M
EPS (ttm) -426.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 314,962
Average Volume 2,128,775
Open 7,050.00
Previous Close 6,980.00
Day's Range 6,720.00 - 7,050.00
52-Week Range 2,750.00 - 8,650.00
Beta 0.54
RSI 57.30
Earnings Date Nov 11, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.